Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Contact information


susan.wagland@ndorms.ox.ac.uk

Susan Wagland

BA, BSc, MSc, PhD

Clinical Trials Manager

Orthopaedic trauma

As Clinical Trials Manager in Oxford Trauma Group I am responsible for day-to-day management of clinical trials:

  • FAME Trial which is in set-up;
  • UKSTAR Trial which has completed follow-up and is being prepared for publication;
  • PATH-2 Study which has met its recruitment target and is being prepared for publication while we complete a long-term follow-up;
  • AIM Trial, which has been published.

The FAME trial is looking at the best treatment for unstable ankle fractures in adults aged up to 60 years old: surgical treatment or non-surgical treatment with close contact casting. The AIM Trial looked at the same treatments for adults aged over 60.

In UKSTAR we want to know whether patients with Achilles tendon ruptures treated non-surgically have a better outcome depending on whether they are immobilised in a plaster cast or an orthopaedic brace (walking boot).

The PATH-2 study is investigating the effect of platelet rich plasma (PRP) as a non-surgical treatment for Achilles tendon ruptures, and the AIM Trial tested a new casting technique for ankle fractures treated without surgery. 

I have three years’ experience of clinical trial management, and prior to working for the University, I spent 15 years in the IT industry, and specialised in project management, data quality and release management. I have also worked in University administration.

During my scientific training, I worked on breast cancer and gained a PhD from Brunel University London in Biology and Biochemistry Research. I also hold a BSc (Hons) in Life Sciences from the Open University and a MSc from Brunel in Molecular Medicine with Cancer Research.